Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Inactivated Poliovirus Vaccine [EPC]
Human Varicella-zoster Immune Globulin is a specialized immune globulin used for post-exposure prophylaxis of chickenpox in high-risk individuals, providing immediate passive immunity.
Name
Human Varicella-zoster Immune Globulin
Raw Name
HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN
Category
Inactivated Poliovirus Vaccine [EPC]
Drug Count
5
Variant Count
5
Last Verified
February 17, 2026
About Human Varicella-zoster Immune Globulin
Human Varicella-zoster Immune Globulin is a specialized immune globulin used for post-exposure prophylaxis of chickenpox in high-risk individuals, providing immediate passive immunity.
Detailed information about Human Varicella-zoster Immune Globulin
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Human Varicella-zoster Immune Globulin.
Human Varicella-zoster Immune Globulin (often referred to by the brand name Varizig) is a sterile, highly purified solution of human plasma containing high titers of antibodies (immunoglobulins) specifically directed against the Varicella-zoster virus (VZV). This virus is the causative agent of both varicella (chickenpox) and herpes zoster (shingles). Human Varicella-zoster Immune Globulin belongs to a class of drugs known as immune globulins or passive immunizing agents. Unlike a vaccine, which stimulates the body's own immune system to produce antibodies over several weeks (active immunity), an immune globulin provides 'ready-made' antibodies that offer immediate, though temporary, protection (passive immunity).
According to the FDA-approved labeling, this product is manufactured from large pools of human plasma collected from donors who have high levels of anti-VZV antibodies. The manufacturing process involves a sophisticated cold ethanol fractionation process (the Cohn-Oncley method) followed by viral inactivation steps to ensure the safety and purity of the final product. The FDA first granted orphan drug designation to Varizig, and it received formal approval for post-exposure prophylaxis in 2012, replacing the older VZIG product that had been discontinued.
At the molecular level, Human Varicella-zoster Immune Globulin works through a process called viral neutralization. When a person is exposed to the Varicella-zoster virus, the virus attempts to enter host cells to replicate. The specific IgG antibodies contained within the immune globulin bind to the surface glycoproteins of the VZV virions (virus particles). This binding prevents the virus from attaching to and entering human cells, effectively 'neutralizing' the threat before it can establish a widespread infection.
Furthermore, these antibodies can promote opsonization (marking the virus for destruction), where the antibody-coated virus is more easily recognized and engulfed by phagocytes (immune cells that eat pathogens). For patients who are immunocompromised (having a weakened immune system), this exogenous (external) source of antibodies is critical because their own bodies cannot mount an effective immune response quickly enough to prevent severe, potentially fatal complications of chickenpox, such as viral pneumonia, encephalitis (brain inflammation), or disseminated varicella.
Understanding the pharmacokinetics (how the body processes the drug) of Human Varicella-zoster Immune Globulin is essential for timing its administration correctly.
The primary FDA-approved indication for Human Varicella-zoster Immune Globulin is post-exposure prophylaxis (prevention) of varicella in high-risk individuals. To be effective, it should be administered as soon as possible after exposure, ideally within 96 hours, though it may be given up to 10 days post-exposure according to CDC guidelines. High-risk groups include:
Human Varicella-zoster Immune Globulin is available exclusively as an injectable solution for intramuscular administration. It is typically supplied in single-dose vials containing 125 International Units (IU) of anti-VZV antibody. The solution is clear or slightly opalescent and should be inspected for particulate matter before use. It is never intended for intravenous injection, as this can increase the risk of severe infusion-related reactions.
> Important: Only your healthcare provider can determine if Human Varicella-zoster Immune Globulin is right for your specific condition. The decision is based on your immune status, the severity of the exposure, and your underlying health risks.
The standard dosage for Human Varicella-zoster Immune Globulin is based on the patient's body weight. According to the manufacturer's guidelines and clinical standards, the recommended dose is 125 International Units (IU) for every 10 kilograms (approximately 22 pounds) of body weight.
This is a one-time administration for a single exposure event. If a second, distinct exposure occurs more than three weeks after the first dose, a repeat dose may be necessary as the passive immunity begins to wane.
Pediatric dosing follows the same weight-based calculation as adult dosing: 125 IU per 10 kg of body weight.
No specific dosage adjustments are required for patients with renal (kidney) impairment, as the drug is not primarily cleared by the kidneys. However, because some immune globulin products have been associated with renal dysfunction, these patients should be monitored closely for hydration and kidney function.
No dosage adjustments are necessary for patients with hepatic (liver) impairment. The metabolism of IgG molecules does not rely on hepatic enzyme pathways.
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.
Human Varicella-zoster Immune Globulin is administered strictly via intramuscular (IM) injection by a healthcare professional. It should not be self-administered.
Because Human Varicella-zoster Immune Globulin is a post-exposure prophylactic treatment given as a single dose, 'missing' a dose in the traditional sense of a daily medication does not apply. However, 'missing the window' is a concern. If the injection is not given within 10 days of exposure, its effectiveness significantly diminishes. If you believe you have been exposed to chickenpox and are at high risk, contact your doctor immediately.
Information on overdosage is limited. Because it is administered by healthcare professionals in a controlled setting, the risk of a significant overdose is low. Symptoms of an overdose might include increased pain or swelling at the injection site or a higher risk of systemic reactions like headache or fever. In the event of an accidental overdose, treatment is supportive.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. If you experience a new exposure after receiving the drug, you must inform your doctor.
The most frequently reported side effects of Human Varicella-zoster Immune Globulin are localized to the site of administration. Because the medication is a protein-rich solution injected into the muscle, some degree of reaction is expected.
These effects are generally mild and self-limiting but may be bothersome to some patients:
Rarely, more significant reactions can occur, often related to the protein nature of the product:
> Warning: Stop taking Human Varicella-zoster Immune Globulin and call your doctor immediately if you experience any of these.
Human Varicella-zoster Immune Globulin is intended for short-term, acute use. There are no known long-term side effects associated with a single prophylactic dose. However, because it is derived from human plasma, there is a theoretical, albeit extremely low, risk of transmitting infectious agents, such as viruses or the agent of Creutzfeldt-Jakob disease (CJD). Modern manufacturing techniques, including solvent/detergent treatment and nanofiltration, have made this risk negligible.
No FDA black box warnings currently exist specifically for Human Varicella-zoster Immune Globulin (Varizig). However, it is important to note that many intravenous immune globulin (IVIG) products carry black box warnings for renal dysfunction and thrombosis. While Varizig is administered intramuscularly, healthcare providers still exercise caution regarding these risks, particularly in patients with pre-existing risk factors for blood clots or kidney disease.
Report any unusual symptoms to your healthcare provider. Even mild symptoms should be documented in the patient's medical record for future reference regarding immune globulin tolerance.
Human Varicella-zoster Immune Globulin must be administered with caution. It is a blood-derived product, and while the risk is minimal, patients should be aware of the nature of the medication. It is not a substitute for the varicella vaccine in healthy individuals; it is strictly for high-risk patients who cannot be vaccinated or who have already been exposed.
No FDA black box warnings for Human Varicella-zoster Immune Globulin. Unlike some other immune globulin products, Varizig has not been mandated to carry a boxed warning, largely due to its intramuscular route of administration and specific use case.
While a single dose of Human Varicella-zoster Immune Globulin does not usually require extensive long-term monitoring, healthcare providers may perform the following:
There is no evidence to suggest that Human Varicella-zoster Immune Globulin interferes with the ability to drive or operate heavy machinery. However, if a patient experiences dizziness or fatigue following the injection, they should avoid these activities until symptoms resolve.
There are no known direct interactions between alcohol and Human Varicella-zoster Immune Globulin. However, alcohol can dehydrate the body and potentially complicate the monitoring of side effects like headaches or dizziness. It is generally advisable to avoid excessive alcohol consumption following any medical procedure or injection.
This medication is given as a single-dose treatment. There is no 'discontinuation' process or tapering required. There is no risk of withdrawal syndrome.
> Important: Discuss all your medical conditions with your healthcare provider before starting Human Varicella-zoster Immune Globulin, especially if you have a history of blood clots, heart disease, or IgA deficiency.
There are no specific 'do not use' drug-drug interactions that result in immediate toxicity. However, the most significant interaction is with Live Virus Vaccines.
There are no known interactions between Human Varicella-zoster Immune Globulin and specific foods, including grapefruit, dairy, or high-fat meals. Because it is administered by injection, the digestive process does not affect its absorption or efficacy.
There are no documented interactions with herbal supplements such as St. John's Wort, ginkgo, or valerian. However, supplements that have mild blood-thinning properties (like high-dose Vitamin E, garlic, or ginger) should be mentioned to the doctor due to the risk of bruising at the injection site.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. The timing of your next scheduled vaccinations is particularly important to discuss.
Conditions where Human Varicella-zoster Immune Globulin must NEVER be used include:
These conditions require a careful risk-benefit analysis by the physician:
There is a potential for cross-sensitivity in patients who are sensitive to other human blood products, such as albumin or other specialized globulins (e.g., Hepatitis B Immune Globulin). There is no cross-sensitivity with vaccines produced in egg cultures, as this is a human-derived plasma product.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Human Varicella-zoster Immune Globulin. Ensure they are aware of any history of 'bad reactions' to blood transfusions or previous injections.
Human Varicella-zoster Immune Globulin is often specifically indicated for pregnant women. According to the CDC and FDA, pregnant women who are exposed to VZV and lack evidence of immunity are at high risk for severe varicella, which can lead to viral pneumonia.
It is not known whether the antibodies in Human Varicella-zoster Immune Globulin are excreted in human milk. However, since IgG is a naturally occurring component of breast milk, the risk to a nursing infant is considered negligible. Breastfeeding is not a contraindication to receiving the injection.
This product is approved for use in children, including neonates (newborns). In fact, neonates are one of the primary target populations.
Elderly patients may be at higher risk for certain complications, such as thrombotic events (blood clots) or renal issues. When treating geriatric patients, healthcare providers will assess cardiovascular health and hydration status before administration. There is no evidence that the drug is less effective in the elderly, but the risk of side effects may be slightly higher due to co-morbidities.
In patients with impaired renal function, there is a theoretical risk of osmotic nephrosis, though this is primarily associated with IVIG products containing sucrose (which Varizig does not). Nonetheless, ensuring the patient is well-hydrated before and after the injection is a standard precautionary measure.
No specific studies have been performed in patients with liver disease. However, because the clearance of IgG is through the reticuloendothelial system and not the liver's metabolic pathways, no dose adjustment is expected to be necessary.
> Important: Special populations require individualized medical assessment. Pregnant women and parents of newborns should discuss the timing of the injection with their obstetrician or pediatrician immediately upon exposure.
Human Varicella-zoster Immune Globulin provides passive immunity by introducing high concentrations of IgG antibodies that have a high affinity for the Varicella-zoster virus (VZV). The molecular mechanism involves the Fab (fragment antigen-binding) portion of the IgG molecule binding to the VZV envelope glycoproteins. This prevents the virus from entering the host cell by blocking the 'lock and key' mechanism required for viral fusion. Additionally, the Fc (fragment crystallizable) portion of the antibody can trigger the complement system and enhance the ability of macrophages to clear the virus through phagocytosis.
The pharmacodynamic effect is the immediate increase in the titer of circulating anti-VZV antibodies. This effect is dose-dependent. The goal is to reach a serum level of antibodies that exceeds the threshold required to neutralize the virus during its incubation period. The duration of this effect typically lasts for 3 to 6 weeks, which covers the period during which a patient would typically develop chickenpox after an exposure.
| Parameter | Value |
|---|---|
| Bioavailability | High (systemic absorption from muscle) |
| Protein Binding | N/A (it is a protein) |
| Half-life | Approximately 26 days |
| Tmax | 3 to 7 days |
| Metabolism | Reticuloendothelial system catabolism |
| Excretion | Not renally excreted (recycled amino acids) |
Human Varicella-zoster Immune Globulin is classified as a 'Passive Immunizing Agent' and an 'Immune Globulin'. It is distinct from the Varicella Vaccine, which is a 'Live Attenuated Vaccine'. Within the therapeutic hierarchy, it is used for post-exposure prophylaxis rather than routine prevention.
Common questions about Human Varicella-zoster Immune Globulin
Human Varicella-zoster Immune Globulin is used to prevent or significantly lessen the severity of chickenpox (varicella) in people who have been recently exposed to the virus and are at high risk for complications. This includes pregnant women who are not immune, newborns whose mothers had chickenpox around the time of delivery, and people with weakened immune systems, such as those undergoing chemotherapy. It is not used to treat an active case of chickenpox or shingles once the rash has already appeared. Instead, it provides 'passive immunity' by giving the body ready-made antibodies to fight the virus during its incubation period. To be most effective, it should be given as soon as possible after exposure, ideally within 96 hours.
The most common side effects are related to the site of the injection, as the medication is a thick, protein-rich solution that must be injected into a muscle. Patients frequently report pain, soreness, or tenderness at the injection site for a day or two following the procedure. Some people also experience systemic symptoms like a mild headache, fatigue, or a low-grade fever as their body processes the new antibodies. Less commonly, patients might feel slightly nauseated or experience chills. These side effects are generally mild and go away on their own without specific treatment. However, if you experience severe pain or signs of an allergic reaction, you should contact your doctor immediately.
There is no known direct interaction between alcohol and Human Varicella-zoster Immune Globulin that would make the medication dangerous or ineffective. However, doctors generally recommend avoiding alcohol for a short period after receiving any major injection or blood product. Alcohol can cause dehydration and might worsen side effects like headaches or dizziness, making it harder to monitor how you are reacting to the medication. Furthermore, if you are in a high-risk group (such as being immunocompromised), alcohol can further stress your immune system. It is best to stay well-hydrated with water and rest after receiving your dose.
Yes, Human Varicella-zoster Immune Globulin is considered safe and is often specifically recommended for pregnant women who have been exposed to chickenpox and do not have immunity. Pregnant women are at a much higher risk for severe complications from chickenpox, such as life-threatening pneumonia. Receiving this injection can help protect the mother from severe illness and may also reduce the risk of the virus being passed to the developing fetus. While it is classified as Pregnancy Category C, the benefits of preventing a severe viral infection in the mother almost always outweigh the potential risks. If you are pregnant and exposed to chickenpox, you should contact your obstetrician immediately.
Human Varicella-zoster Immune Globulin begins to work as soon as the antibodies enter your bloodstream, but it takes some time for the full dose to be absorbed from the muscle. Peak levels of the antibodies in the blood are typically reached between 3 and 7 days after the injection. Because the incubation period for chickenpox is usually 10 to 21 days, the injection is designed to provide protection before the virus has a chance to fully replicate and cause disease. This is why timing is so critical; the sooner the antibodies are present, the better they can neutralize the virus. Even if it doesn't completely prevent the infection, it often makes the resulting illness much milder.
Human Varicella-zoster Immune Globulin is administered as a single, one-time dose by a healthcare professional, so there is no regimen to 'stop' or 'discontinue.' It is not a daily medication like a pill. Once the injection is given, the antibodies remain in your system for several weeks, gradually being broken down and cleared by your body naturally. There are no withdrawal symptoms or 'rebound' effects associated with this medication. If you were exposed to the virus again several weeks later, you would need to consult your doctor to see if a second dose is necessary, as the protection from the first dose eventually fades.
Since this is a one-time emergency treatment given after exposure to a virus, you cannot 'miss' a dose in the way you might miss a daily vitamin. However, if you were supposed to receive the injection and didn't, the 'window of opportunity' to prevent the disease might close. The medication is most effective when given within 96 hours (4 days) of exposure, though it can still be beneficial up to 10 days after. If you have been exposed and have not yet received the injection, call your healthcare provider or visit an urgent care center immediately. Delaying the dose increases the risk that the virus will establish an infection that the antibodies can no longer stop.
No, Human Varicella-zoster Immune Globulin does not cause weight gain. It is a single-dose protein injection used for short-term prevention of a viral infection. It does not contain hormones, steroids, or any ingredients that affect metabolism or appetite in a way that would lead to weight changes. Any swelling that occurs is typically localized to the site of the injection and is temporary. If you notice sudden or unusual weight gain or swelling in your legs after receiving this medication, you should contact your doctor, as this could be a sign of a different medical issue, such as a heart or kidney problem, rather than a side effect of the immune globulin itself.
In most cases, yes, Human Varicella-zoster Immune Globulin can be taken alongside other medications. However, it is very important to tell your doctor if you are taking blood thinners (anticoagulants), as an injection into the muscle could cause significant bruising or bleeding. The most important 'interaction' is with vaccines. Because this medication contains antibodies against the varicella virus, it can interfere with live vaccines like the MMR (measles, mumps, rubella) or the varicella vaccine itself. You will typically need to wait 3 to 5 months after receiving the immune globulin before you can get any live-virus vaccines to ensure they work correctly.
Human Varicella-zoster Immune Globulin is a complex biological product derived from human plasma, and it is not available as a 'generic' in the way that simple chemical drugs like aspirin or lisinopril are. In the United States, the primary brand available is Varizig. While there may be other immune globulin products used in different countries, they are all specialized 'biologics.' Because the manufacturing process is so complex and requires a specific pool of donors with high antibody levels, these products are generally more expensive and less widely available than standard medications. Your insurance and healthcare provider will determine which specific brand or product is available for your treatment.